How GLP-1 Users Became REP Provisions' Largest Customer Base, and Why

Quick Answer

When GLP-1 medications like Ozempic and Wegovy first hit the mainstream, appetite suppression meant people ate less of everything, including our meat. Revenue flattened across the food industry. But as users stayed on these drugs longer, their bodies started burning through muscle and bone density along with fat. The body recognized this wasn't a short-term diet; it was a sustained nutrient shortage. So the brain reprioritized: less appetite for sugar and empty carbs, more demand for dense, high-quality protein and fat. That's exactly what REP Provisions was built to deliver. Because we start at the soil, our meat carries more of the nutrients a GLP-1 body is now desperately asking for, which is why this customer segment has become our fastest-growing, highest-loyalty group, while ultra-processed food brands are seeing the opposite effect.

The First Wave: GLP-1s Looked Like a Threat to Every Food Business

When GLP-1 receptor agonists went mainstream, the food industry braced for impact, and rightly so. These drugs suppress appetite and slow digestion, and the early data was stark: users were eating meaningfully less across the board. Research from Cornell found grocery spending per trip dropped between roughly 5% and 8% after adoption, with restaurant spending down about 8% in the first six months of use.

The hit wasn't evenly distributed even in that first wave. Ultra-processed, calorie-dense categories like sweet and savory snacks fell around 10%, but so did some staples, including meat and eggs. For a business like ours, that stung. We weren't selling junk food, but appetite suppression doesn't discriminate at first. If someone is eating less overall, every category feels it, at least initially.

The Turn: The Body Realizes This Isn't a Temporary Diet

Here's where the story changes, and it's the part most food brands still haven't caught up to.

The longer someone stays on a GLP-1, the more their body starts losing lean muscle mass and bone density alongside fat, simply because they're consuming far fewer total calories and nutrients. At some point, the body stops treating this like a short-term calorie dip and starts treating it like a sustained nutrient shortage. It's not getting what it needs to maintain muscle, bone, and basic function, and that's not sustainable indefinitely.

So the signaling shifts. The brain doesn't need to protect against a famine of calories anymore; appetite is already suppressed. What it needs to protect is nutrient density. Sugar and refined carbs deliver a lot of calories and very little of what the body is now starving for. Protein, healthy fats, vitamins, and minerals deliver the raw material for muscle and bone. So cravings and food-seeking behavior tilt hard toward those categories.

This isn't just anecdotal; it shows up clearly in the data:

• A multi-study review of GLP-1 eating behavior found users show a meaningfully higher willingness to pay for protein products, becoming up to 0.22 points less price-sensitive on protein specifically compared to non-users, with direct implications for meat, dairy, and other protein categories.
• Acosta Group purchase data found 31% of GLP-1 users buying more fresh chicken and 32% buying more yogurt, while Wells Fargo/NielsenIQ research found fresh meat purchases up 15% and cheese up 16% among this group.
• A University of Arkansas study found GLP-1 users cut roughly 700 calories a day, and the foods they eliminated first were processed foods, sugar-sweetened drinks, refined grains, and notably beef, while other protein sources gained ground.
• Agweek reporting on the agricultural side describes influencers now sharing high-protein, whole-food meals with their followers, a cultural shift that food industry analysts say is directly tied to the rise of these medications and the parallel focus on preventing muscle loss.
• Even national restaurant chains have restructured menus around this shift: Chipotle's high-protein "Protein Cups," Shake Shack's lettuce-wrapped "Good Fit" menu, and Smoothie King's dedicated GLP-1 menu are all direct responses to customers who want less bulk and more nutrient density per bite.

Why REP Provisions Is Positioned to Win This Customer

This is where our whole business model becomes the answer to a question most of the food industry is only now starting to ask.

We didn't build REP Provisions around marketing a "high protein" label. We built it around the actual source of nutrient density: the soil. Healthy soil grows healthier plants. Healthier plants raise healthier, better-nourished animals. And animals raised on genuinely nutrient-rich land produce meat that carries more of what a depleted body is signaling for, not just protein grams on a label, but the fuller nutrient profile that comes from doing it right at the root.

That's a very different value proposition than a chain restaurant bolting a "protein cup" onto an existing menu. A GLP-1 customer's body isn't asking for a marketing category; it's asking for density and quality, meal after meal, indefinitely. That's a long-term relationship, not a trend to chase.

And the macro trend backs up why this matters. Circana projects GLP-1 users could account for as much as 35% of all food and beverage sales by 2030. Morgan Stanley estimates up to 24 million Americans could be using these medications by 2035. This isn't a fad segment. It's becoming a structural share of the market, and it's actively rewarding the exact thing REP has always focused on.

Meanwhile, the Other Side of the Ledger

While REP has been gaining this customer, the numbers on the other side of the industry tell the flip story. Analysts estimate sales of carbonated soft drinks, baked goods, and salty snacks could decline roughly 3% over the next decade due to GLP-1 adoption alone. Snacking frequency among users has dropped sharply: Morgan Stanley found 66% of GLP-1 users cut daily snacking from three-plus times down to two or fewer. Dinner traffic at fast-food chains has fallen among regular users, and companies across categories, from apparel to packaged snacks, are citing GLP-1s directly in their own financial filings as a structural headwind.

Big Food knows it. Editorial coverage in trade and medical press alike now frames this openly as legacy packaged-food companies scrambling to reformulate and "outsmart" a demand shift that isn't going away. REP didn't have to pivot into this moment. The moment arrived at our front door because of a foundation we'd already built.

Key Takeaways

• GLP-1s initially suppressed appetite across the board, temporarily flattening revenue for food businesses of every kind, REP included.
• Sustained GLP-1 use causes real losses in muscle mass and bone density, signaling to the body that this is a long-term nutrient shortage, not a short diet.
• In response, the body deprioritizes sugar and refined carbs and prioritizes nutrient-dense protein and healthy fats, a shift confirmed by multiple industry and academic studies.
• Purchase data shows GLP-1 users buying significantly more chicken, fresh meat, cheese, and yogurt, while cutting snacks, sugary drinks, and refined carbs.
• REP Provisions' soil-first approach means our meat is positioned to deliver exactly the nutrient density this customer's body is demanding, not a marketing add-on, but the actual product of how the animals were raised.
• Ultra-processed food and legacy snack brands are seeing measurable, structural sales declines tied to GLP-1 adoption, while whole-food, high-quality protein categories are gaining.
• This isn't a passing trend. GLP-1 usage is projected to keep growing for years, making nutrient-dense protein sourcing a long-term structural advantage, not a short-term marketing angle.

Frequently Asked Questions

Why did GLP-1 drugs hurt meat sales at first, if protein is supposed to be good for users? Early on, appetite suppression reduced total food intake across nearly every category, including meat and eggs, simply because people were eating less of everything. The shift toward protein specifically happened later, once sustained use started causing muscle and bone density loss. That's when the body's priorities changed from "eat less" to "get more nutrient density per bite."

Is the muscle and bone loss from GLP-1 use dangerous? Losing lean muscle mass and bone density alongside fat is a well-documented effect of significant, sustained weight loss, including on GLP-1 medications. It's part of why doctors and dietitians increasingly emphasize adequate protein intake and resistance training for people on these drugs. If you're on a GLP-1 medication, it's worth talking with your doctor or a dietitian about your specific protein and nutrient needs.

What makes REP Provisions' meat more nutrient-dense than other meat? We focus on the health of the soil first. Healthier soil grows more nutrient-rich forage and feed, which produces healthier animals, which in turn produces meat with a richer nutrient profile, not just more protein by weight, but better overall nutrient density.

Is this GLP-1 shift toward protein really a long-term trend, or will it fade? Every major analysis points to this being structural rather than temporary. Usage rates are projected to keep climbing for at least the next decade, and industry analysts expect GLP-1 users to represent a large and growing share of total food and beverage spending.

Do you have to be on a GLP-1 medication to benefit from REP Provisions' meat? Not at all. Nutrient-dense, soil-first meat benefits anyone looking to get more real nutrition per meal, whether or not they're on a weight-loss medication. GLP-1 users are simply the customer segment where that need has become most urgent and most visible.

What food categories are losing the most ground because of GLP-1s? Ultra-processed snacks, sugary beverages, baked goods, and alcohol have seen the steepest declines, since these deliver calories with relatively little of the nutrient density a GLP-1 body is now prioritizing.